Cardinal Health, Inc.

🇺🇸New York Stock Exchange
Back to all articles
Cardinal Health, Inc. stock analysis CAH overview
Bearish -50

Cardinal Health is getting pummeled on mixed results — here's our plan for stock

📉 Cardinal Health shares are dropping after reporting mixed quarterly results that disappointed investors on revenue but beat earnings estimates.

💰 Revenue for the quarter ended March 31 grew 11% year-over-year to $60.94 billion, missing analyst expectations of $61.7 billion according to LSEG.

🧮 Adjusted earnings per share came in at $3.17, which beat the consensus estimate of $2.79 compiled by LSEG.

⚠️ Jim Cramer described the company's performance as "Good, not great" during his Morning Meeting segment on Thursday.

📉 While overall profitability remained strong and free cash flow tripled Street estimates, sales missed targets across all three operating segments.

🏭 The Global Medical Products and Distribution segment faced significant challenges due to lower distribution volumes and the negative impact of tariffs.

💊 Revenue in the Pharmaceutical and Specialty Solutions segment rose 11% to $56.2 billion, driven by strong demand for GLP-1 weight-loss drugs which grew over 30%.

📉 The Other segment saw a 31% revenue increase to $1.7 billion, though it still fell short of Wall Street expectations.

⚖️ In Global Medical Products and Distribution, profits plummeted by 35% year-over-year primarily due to tariff-related costs offsetting revenue gains from brand products.

🔼 Management raised its full-year earnings outlook, but noted that only 13 cents of the $0.50 increase stems from operational improvements rather than taxes or expenses.

📉 The stock is currently trading around $190 with a forward P/E ratio of 16x fiscal year 2027 estimates, which is at the lower end of its valuation range over the past year.

⚠️ Analysts are maintaining their "Buy" rating but trimming the price target from $260 to $225 while waiting for more clarity on the situation.

📉 Technical indicators show the stock has entered oversold territory with a Relative Strength Index (RSI) cross, suggesting significant pessimism is baked into the price.

🛑 The stock is hovering near its 200-day moving average support level after being down more than 6%, making investors cautious about rushing in at the dip.

🏢 CEO Jason Hollar emphasized that cost optimization initiatives are delivering results while the company navigates a dynamic and challenging tariff environment.

Bullish Signals
  • Revenue for the three months ended March 31 increased 11% year over year to $60.94 billion, demonstrating solid top-line growth despite missing high expectations.
  • Adjusted earnings per share (EPS) came in at $3.17, significantly beating the consensus estimate of $2.79 by approximately 14%.
  • Free cash flow was three times the Street's consensus estimate, indicating strong operational efficiency and cash generation capabilities.
  • Management raised its full-year earnings outlook, signaling confidence in the company's long-term trajectory despite recent mixed results.
  • Revenue in the Pharmaceutical and Specialty Solutions segment increased 11% year over year to $56.2 billion, driven by strong demand for brand and specialty pharmaceuticals.
  • The company reported a more than 30% revenue growth for obesity and weight-loss medicines (GLP-1 drugs), contributing significantly to segment revenue expansion.
  • In the Other segment, revenue surged 31% year over year to $1.7 billion, driven by growth across Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight Logistics.
  • CEO Jason Hollar highlighted tangible results from simplification and cost optimization initiatives, along with notable strength in the Cardinal Health brand product portfolio.
Risk Factors
  • Revenue missed expectations by $666 million for the quarter, with total revenue at $60.94 billion versus the consensus estimate of $61.7 billion.
  • The Pharmaceutical and Specialty Solutions segment revenue shorted estimates by $1.36 billion, arriving at $56.2 billion against an expected $57.56 billion.
  • Global Medical Products and Distribution sales were held back by lower distribution volumes, resulting in revenue missing expectations despite offsetting brand growth.
  • Segment profit for Global Medical Products and Distribution plummeted 35% year over year to a low of $3.25 billion, largely due to negative impact from tariffs.
  • The stock is down more than 6% from its recent highs and trading around the critical 200-day moving average support level.
  • Analyst price target has been trimmed significantly from $260 to $225 following the mixed earnings report and sell-off.
  • Only 13 cents of the 50-cent full-year earnings midpoint increase is attributable to operational performance, with the remainder driven by non-operational factors like taxes and share repurchases.
  • The stock is trading at 16 times fiscal year 2027 estimates, which is near the lowest valuation level seen since October of the previous year.
Full Analysis
Shares of Cardinal Health (CAH) fell more than 6% on Thursday following the release of mixed quarterly results for the period ending March 31. While revenue grew 11% year over year to $60.94 billion, it missed analyst expectations of $61.7 billion across all three operating segments. Despite the revenue miss, adjusted earnings per share (EPS) beat consensus estimates at $3.17 compared to the expected $2.79, and free cash flow reached three times the Street's estimate. Jim Cramer characterized the performance as "good, not great," noting that while overall profitability remained strong, the Global Medical Products and Distribution segment was significantly weighed down by tariff exposure and lower distribution volumes. The company management raised its full-year earnings outlook by 50 cents at the midpoint, but noted that only 13 cents of this increase is driven by improved operational performance, with the remainder coming from tax benefits, share repurchases, and interest/other expenses. Revenue in the Pharmaceutical and Specialty Solutions segment rose 11% to $56.2 billion, fueled largely by a 30% surge in revenue for obesity and weight-loss medicines (GLP-1s), which contributed a 6-percentage-point increase to segment revenue. Conversely, Global Medical Products and Distribution revenue was flat at $3.25 billion, though segment profit plummeted 35% year over year due to tariffs. The Other segment saw a robust 31% revenue increase to $1.7 billion, driven by growth in Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight Logistics. Analysts are reacting to the mixed report by adjusting their positions on the stock. At a trading price of approximately $190, shares are valued at about 16 times fiscal year 2027 estimates, marking the lowest multiple seen since October and entering oversold territory based on the Relative Strength Index (RSI). Although the valuation sits on the lower end of the historical range of 15-21 times, the stock remains near its 200-day moving average. Consequently, the analysts have trimmed their price target from $260 to $225 and are maintaining a "Buy" rating, advising patience while the market digests the sell-off. CEO Jason Hollar reiterated the company's strategic focus on simplification, cost optimization, and supply chain resiliency as they navigate the dynamic tariff environment.